Dyslipidaemia, statins and rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 4, 2009, Pages 453-455

  Nurmohamed, Michael T ^a,b   Dijkmans, Ben A C ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EDITORIAL; EPIDEMIOLOGICAL DATA; HUMAN; HYPERLIPIDEMIA; NONHUMAN; OSTEOLYSIS; OXIDATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; BLOOD;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; DISEASE SUSCEPTIBILITY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TRIGLYCERIDES;

EID: 65249170044     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.104497     Document Type: Editorial

References (25)

1. Solomon DH, Greenberg J, Reed G, Setoguchi S, TsaoP, Kremer J. Cardiovascular risk among patients with RA in CORRONA: comparing the explanatory value of traditional cardiovascular risk factors with RA risk factors. Ann Rheum Dis 2008;67(Suppl 2):482.
2. van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross sectional study. The CARRE Investigation. Ann Rheum Dis. Published Online First: 12 August 2008. doi:10.1136/ard.2008.094151
3. Peters MJL, van Halm VP, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis as important independent risk factor for incident cardiovascular disease. Arthritis Rheum 2008;58(Suppl): S421-2.
4. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
5. van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation - serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8.
6. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
7. Hyka N, Dayer JM, Modoux C, Kono T, Edwards CK, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukinb and tumor necrosis factor-a by blocking contact mediated activation of monocytes by T-lymphocytes. Blood 2001;97:2381-9.
8. Ashby DT, Rye KA, Clay, MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterio Thromb Vasc Biol 1998;18:1450-5.
9. Ansell BJ, Navab M, Watson KE, Fonarow GC, Fogelman AM. Anti-inflammatory properties of HDL. Rev Endocr Metab Disord 2004;5:351-8.
10. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17.
11. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY. Proinflammatory highdensity lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
12. Charles-Schoeman C, Lee YY, Furst DE, Paukus HE, McMahon M, Fogelman AM, et al. Methotrexate improves HDL's anti-inflammatory properties in patients with systemic rheumatic disease. Arthritis Rheum 2008;58(Suppl): S271.
13. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Clin. Invest 2007;107:1423-32.
14. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007;34:1459-64.
15. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9.
16. Funk JL, Chen J, Downey KJ, Clark RA. Bone protective effect of simvastatin in experimental arthritis. J Rheumatol 2008;35:1083- 91.
17. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607-11.
18. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
19. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
20. Takagi T, Matsuda M, Abe M, Kobayashi H, Fukuhara A, Komuro R, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008;196:114-21.
21. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis. Published Online First: 28 July 2008. doi:10.1136/ard.2008.091967
22. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-24.
23. Watts G. What happened to the polypill? BMJ 2008;337:a1822.
24. Clinical Trials Unit, Department of Medicine, Auckland University. PILL pilot: Programme to Improve Life and Longevity. http://www.ctru. auckland.ac.nz/content/view/37/35/(accessed 24 December 2008).
25. Peters MJ, Symmons DPM, McCarey DW. Nurmohamed MT. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - a EULAR task force. Arthritis Rheum 2008;58(Suppl): S421.